NEWNAN, Georgia, December 1 /PRNewswire/ -- CeloNova BioSciences, Inc., a provider of specialty surface treatments for medical devices and of specialty implants, today announced that Barry Katzen, MD, FACR, FACC, FSCAI, founder and medical director of Baptist Cardiac Vascular Institute in Miami, Florida, will discuss the CATANIA(TM) Stent System with NanoThin Polyzene(R)-F at the Innovations in Cardiovascular Interventions Conference to be held at the Hotel David InterContinental in Tel Aviv, Israel, which will include new information about the stent's coating, Polyzene(R)-F, and clinical outcomes in coronary, below-the-knee, and neurovascular applications. We are deeply honored that Dr. Katzen will present these data at the ICI conference where innovation is recognized and celebrated. We believe the CATANIA(TM) stent is the technological breakthrough that interventional cardiologists have needed to dispense with the problems associated with bare metal and drug-eluting stents, said Thomas A. Gordy, President and chief Executive Officer of CeloNova. Dr. Katzen is a true pioneer in interventional medicine.
About CeloNova BioSciences: Headquartered in Newnan, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are enhanced by one of the Company's proprietary materials, Polyzene(R)-F, a lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant surface treatment for implanted medical devices. The Company's current products include Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. Both products are CE Marked. Embozene(TM) Microspheres have been approved by the FDA for the treatment of hypervascularized tumors and arteriovenous malformations. For more information, please visit www.celonova.com.
About Innovations in Cardiovascular Interventions: The ICI meeting for interventional cardiologists, innovators, and industry will be held December 6-8, in Tel-Aviv, Israel. It is a continuation of the series of interventional cardiology conferences held in Israel since 1995. The upcoming meeting will focus on innovative technology, therapies, and research at various levels of development, with thematic live case presentations to present the impact of these technologies on current and future therapy.
Contact: Theresa Wilson +1-770-502-0304; +1-678-895-6486
SOURCE: CeloNova BioSciences, Inc.
CONTACT: Theresa Wilson +1-770-502-0304; +1-678-895-6486